Related Experiment Videos
[Effect of systemic thrombolytic therapy on necrotic focus formation in myocardial infarct patients]
Insights
Systemic thrombolytic therapy significantly limits myocardial infarction extent by stabilizing necrotic areas. This treatment reduced infarct size by 37.4% compared to controls, demonstrating a clear clinical benefit.
Area of Science:
- Cardiology
- Biochemistry
Context:
- Assessing myocardial infarction progression using precardial charting and CPK enzyme analysis.
- Evaluating the efficacy of systemic thrombolytic therapy in acute myocardial infarction patients.
Purpose:
- To determine the effect of early systemic thrombolytic therapy on myocardial infarct size and clinical outcomes.
- To compare the extent of myocardial necrosis in patients treated with thrombolytic drugs versus a control group.
Summary:
- Systemic thrombolytic therapy, initiated within 6 hours of disease onset, effectively limits the extent of myocardial infarction.
- Precardial charting and serial CPK-MB fraction determination were used to assess infarct stabilization.
- Patients receiving thrombolytic therapy showed a 37.4% reduction in myocardial infarction extent compared to the control group.
Impact:
- Demonstrates a significant beneficial clinical effect of early thrombolytic therapy in reducing myocardial infarct size.
- Highlights the importance of timely intervention in managing acute myocardial infarction.
- Provides evidence for the effectiveness of thrombolytic agents in limiting ischemic damage.
Abstract:
The formation of the myocardial necrotic focus was assessed by precardial charting at 35 leads and the serial determination of CPK activity and MB fraction in 50 patients receiving the systemic thrombolytic therapy and 52 patients of the control group. Thrombolytic therapy initiated within the first 6 h of the disease was shown to facilitate the limitation of the extent of myocardial infarction through a more rapid stabilization of the necrotic focus. The calculated extent of myocardial infarction in patients treated with thrombolytic drugs was 37.4% less than in the control group. A beneficial clinical effect of thrombolytic therapy was demonstrated.